Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02817841 · ClinicalTrials.gov registry record · Phase 3
E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study
A Phase 3 study, sponsored by Estetra.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,148
- Enrollment target
NCT02817841 is a Phase 3 study that has completed, run by Estetra. The registered enrollment target is 2,148 participants.
The verdict
NCT02817841, a Phase 3 study, has completed, sponsored by Estetra.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,148 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in healthy women aged 16 to 50 years.
Interventions
- DRUG 15 mg E4/3 mg DRSP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,148 participants |
| Start Date | 2016-08-30 |
| Est. Completion | 2018-11-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02817841
The ClinicalTrials.gov registry entry for NCT02817841 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Estetra, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 15 mg E4/3 mg DRSP is the first listed.
NCT02817841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02817841 about?
NCT02817841 is a clinical study titled "E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study". The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in healthy women aged 16 to 50 years.
What is the current status of trial NCT02817841?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,148 participants. The study started on 2016-08-30. Estimated completion is 2018-11-16.
What interventions are being tested in trial NCT02817841?
The interventions under investigation include: 15 mg E4/3 mg DRSP (DRUG).
Who is sponsoring clinical trial NCT02817841?
This trial is sponsored by Estetra, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.